|
Basic Characteristics of Mutations
|
|
Mutation Site
|
D614G |
|
Mutation Site Sentence
|
The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
S |
|
Standardized Encoding Gene
|
S
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
COVID-19
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
33767200
|
|
Title
|
The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
|
|
Author
|
Zou J,Xie X,Fontes-Garfias CR,Swanson KA,Kanevsky I,Tompkins K,Cutler M,Cooper D,Dormitzer PR,Shi PY
|
|
Journal
|
NPJ vaccines
|
|
Journal Info
|
2021 Mar 25;6(1):44
|
|
Abstract
|
Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7-2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinical trial.
|
|
Sequence Data
|
-
|
|
|